Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL22129268 | 0.97 | CYP1A2 (0.30) | CYP1A2CYP2A6TSHRTDP2NSD2 | |
| Water SCHEMBL22163766 | 0.97 | CYP1A2 (0.30) | CYP1A2CYP2A6TSHRTDP2NSD2 | |
| Hydrochloric Acid SCHEMBL22129239 | 0.97 | CYP1A2 (0.30) | CYP1A2CYP2A6TSHRTDP2NSD2 | |
| SCHEMBL9839922 | 0.78 | TAAR1 (0.34) | CYP1A2CYP2A6TSHRTDP2NSD2 | |
| SCHEMBL598503 | 0.76 | TDP2 (0.37) | CYP1A2CYP2A6TSHRTDP2NSD2 | |
| SCHEMBL31095112 | 0.76 | TDP2 (0.37) | CYP1A2CYP2A6TSHRTDP2NSD2 | |
| SCHEMBL8436160 | 0.76 | CYP1A2 (0.32) | CYP1A2CYP2A6TSHRTDP2NSD2 | |
| SCHEMBL803140 | 0.75 | TDP2 (0.31) | TDP2NSD2HSP90AA1PAX8 | |
| SCHEMBL1343352 | 0.74 | IDO1 (0.35) | CYP1A2CYP2A6TSHRTDP2NSD2 | |
| SCHEMBL358606 | 0.74 | PDCD1 (0.43) | CYP1A2CYP2A6TSHRTDP2NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556211-B2 | Metal complex compound, hydrogen production catalyst and hydrogenation reaction catalyst each comprising the metal complex compound, and hydrogen production method and hydrogenation method each using the catalyst | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2017-01-31 | — | — | US | disclosed |
| EP-2644611-A1 | METAL COMPLEX COMPOUND, HYDROGEN PRODUCTION CATALYST AND HYDROGENATION REACTION CATALYST EACH COMPRISING THE METAL COMPLEX COMPOUND, AND HYDROGEN PRODUCTION METHOD AND HYDROGENATION METHOD EACH USING THE CATALYST | National University Corporation Okayama University (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-20130244865-A1 | Metal Complex Compound, Hydrogen Production Catalyst and Hydrogenation Reaction Catalyst Each Comprising the Metal Complex Compound, and Hydrogen Production Method and Hydrogenation Method Each Using the Catalyst | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20130126090-A1 | POLY(METH)ACRYLATE-BASED PRESSURE-SENSITIVE ADHESIVE | TESA SE (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20060057366-A1 | Poly(meth) acrylate-based pressure-sensitive adhesive | TESA SE (DE) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244865-A1 | Metal Complex Compound, Hydrogen Production Catalyst and Hydrogenation Reaction Catalyst Each Comprising the Metal Complex Compound, and Hydrogen Production Method and Hydrogenation Method Each Using the Catalyst | MC3R, HRH3, ME3 | CYP1A2 2829/4885CYP2A6 3983/4885TSHR 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.